Trial Profile
Phase II randomized, multicenter, crossover clinical trial for administration of exemestane vs. anastrozole as first line treatment for postmenopausal patients with hormone receptor positive advanced breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Exemestane (Primary) ; Anastrozole
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 29 Jun 2011 Results published in the Cancer.
- 24 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Feb 2006 New trial record.